Epigenetic Marker for Chemotherapy Failures
Patent Number: Pending
Executive Summary:
General Description:
Acute Myeloid Leukemia (AML) is the most common leukemia in adults and second most common leukemia in children. There is a huge need to provide effective treatment and improve the outcome for those affected by this disease. Currently, patients with AML are treated with standard chemotherapy. While some will respond well to this treatment, others will not, making it difficult to predict which patients will respond to specific types of therapy.
Researchers have identified a DNA methylation marker to identify subsets of patients that do not respond to standard chemotherapy. The marker can be used to predict which patients will respond positively to treatment prior to treatment with chemotherapy. By identifying the most effective therapy for treating cancer and other related disease, the patient has a lower chance of having the disease relapse.
Patent Status: Application submitted
Publications:
Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Möllgård L, Hellström-Lindberg E, Jendholm J, Porse BT, Jones PA, Liang G, Grønbæk K. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012 Jan 5;119(1):206-16. doi: 10.1182/blood-2011-06-362541. Epub 2011 Nov 4. Erratum in: Blood. 2013 Jun 20;121(25):5104. Möllgaard, Lars [corrected to Möllgård, Lars]. PubMed PMID: 22058117; PubMed Central PMCID: PMC3251229.
Inventor Bio: Gangning Liang
http://keck.usc.edu/faculty/gangning-liang/
Executive Summary:
- Invention Type: Diagnostic
- Patent Status: Patent pending
- Patent Link: http://usc.flintbox.com/public/project/31474/
- Research Institute: University of Southern California
- Disease Focus: Cancer
- Lead Challenge Inventor: Gangning Liang
- Development Stage: Validated in several clinical trials for adults and children with AML
- Novelty:
- Identification of epigenetic (DNA methylation) biomarker for chemotherapy-resistant AML
- Clinical Applications:
- Diagnostic of acute myeloid leukemia
General Description:
Acute Myeloid Leukemia (AML) is the most common leukemia in adults and second most common leukemia in children. There is a huge need to provide effective treatment and improve the outcome for those affected by this disease. Currently, patients with AML are treated with standard chemotherapy. While some will respond well to this treatment, others will not, making it difficult to predict which patients will respond to specific types of therapy.
Researchers have identified a DNA methylation marker to identify subsets of patients that do not respond to standard chemotherapy. The marker can be used to predict which patients will respond positively to treatment prior to treatment with chemotherapy. By identifying the most effective therapy for treating cancer and other related disease, the patient has a lower chance of having the disease relapse.
Patent Status: Application submitted
Publications:
Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Möllgård L, Hellström-Lindberg E, Jendholm J, Porse BT, Jones PA, Liang G, Grønbæk K. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012 Jan 5;119(1):206-16. doi: 10.1182/blood-2011-06-362541. Epub 2011 Nov 4. Erratum in: Blood. 2013 Jun 20;121(25):5104. Möllgaard, Lars [corrected to Möllgård, Lars]. PubMed PMID: 22058117; PubMed Central PMCID: PMC3251229.
Inventor Bio: Gangning Liang
http://keck.usc.edu/faculty/gangning-liang/
